Biota inks $102M collaboration for Hep C program

Australia's Biota has signed a $102 million pact to collaborate with Germany's Boehringer Ingelheim on a new therapy for Hepatitis C. The agreement covers Biota's nucleoside analogues product for hep C and other diseases. Biota gains immediate research support in the deal along with milestones and future royalties. Exact terms were not disclosed.

- here's the report on the pact from The Age

Suggested Articles

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.

Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.

Immuno-oncology biotech Iovance Biotherapeutics’ shares rocketed up by nearly 40% Tuesday on buyout chatter.